Published in J Clin Endocrinol Metab on January 08, 2008
Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med (2010) 3.26
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes (2013) 1.84
Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation. Am J Physiol Heart Circ Physiol (2009) 1.63
Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol (2009) 1.61
AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol (2011) 1.46
High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol (2008) 1.41
Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.38
A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res (2009) 1.31
Diabetic nephropathy and extracellular matrix. J Histochem Cytochem (2012) 1.28
Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes (2012) 1.24
Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol (2010) 1.22
The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther (2011) 1.12
A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta (2008) 1.12
Evidence for consistency of the glycation gap in diabetes. Diabetes Care (2011) 1.12
Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics (2009) 1.08
Oxidative injury is a common consequence of BMPR2 mutations. Pulm Circ (2011) 1.06
Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract (2010) 1.06
Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res (2012) 1.03
Type 2 diabetes is associated with altered NF-κB DNA binding activity, JNK phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS. PLoS One (2011) 1.00
Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. PLoS One (2011) 1.00
Role of T cells in type 2 diabetic nephropathy. Exp Diabetes Res (2011) 0.99
Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front Aging Neurosci (2010) 0.98
Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev (2014) 0.97
Biomarkers in diabetic retinopathy and the therapeutic implications. Mediators Inflamm (2013) 0.97
Exploring post-translational arginine modification using chemically synthesized methylglyoxal hydroimidazolones. J Am Chem Soc (2012) 0.97
High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant (2011) 0.97
Diagnosing diabetes with glucose criteria: worshiping a false God. Diabetes Care (2011) 0.96
Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue. Diabetes (2009) 0.94
Mesenteric resistance arteries in type 2 diabetic db/db mice undergo outward remodeling. PLoS One (2011) 0.94
Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects. J Proteome Res (2011) 0.93
Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. Open Cardiovasc Med J (2010) 0.92
The ubiquitous conserved glycopeptidase Gcp prevents accumulation of toxic glycated proteins. MBio (2010) 0.92
Up-regulated expression of advanced glycation end-products and their receptor in the small intestine and colon of diabetic rats. Dig Dis Sci (2011) 0.92
Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology. Br J Pharmacol (2012) 0.92
Inhibition of advanced glycation end products by red grape skin extract and its antioxidant activity. BMC Complement Altern Med (2013) 0.91
Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS One (2012) 0.91
Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Res Ther (2011) 0.91
Glycated hemoglobin and risk of hypertension in the atherosclerosis risk in communities study. Diabetes Care (2012) 0.91
Increasing glucose 6-phosphate dehydrogenase activity restores redox balance in vascular endothelial cells exposed to high glucose. PLoS One (2012) 0.91
TNF-α and microalbuminuria in patients with type 2 diabetes mellitus. J Diabetes Res (2014) 0.90
Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids (2010) 0.90
Copper and anesthesia: clinical relevance and management of copper related disorders. Anesthesiol Res Pract (2013) 0.90
The succinated proteome. Mass Spectrom Rev (2013) 0.89
Activation of Akt by advanced glycation end products (AGEs): involvement of IGF-1 receptor and caveolin-1. PLoS One (2013) 0.88
Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. Microsc Microanal (2012) 0.88
Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol (2011) 0.87
Role of Glycated Proteins in the Diagnosis and Management of Diabetes: Research Gaps and Future Directions. Diabetes Care (2016) 0.87
Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia. Front Endocrinol (Lausanne) (2014) 0.87
Association of glycation gap with mortality and vascular complications in diabetes. Diabetes Care (2013) 0.87
Advanced glycation end products measured by skin autofluorescence in a population with central obesity. Dermatoendocrinol (2012) 0.87
High dietary advanced glycation end products are associated with poorer spatial learning and accelerated Aβ deposition in an Alzheimer mouse model. Aging Cell (2016) 0.87
Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature. Front Endocrinol (Lausanne) (2013) 0.87
The question is, my dear watson, why did the dog not bark?: the joslin 50-year medalist study. Diabetes Care (2011) 0.84
A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem (2014) 0.84
Amadori glycated proteins: role in production of autoantibodies in diabetes mellitus and effect of inhibitors on non-enzymatic glycation. Aging Dis (2012) 0.84
Morphometric analysis of connective tissue sheaths of sural nerve in diabetic and nondiabetic patients. Biomed Res Int (2014) 0.83
Circulating TGF-β1, glycation, and oxidation in children with diabetes mellitus type 1. Exp Diabetes Res (2012) 0.83
AGEs secreted by bacteria are involved in the inflammatory response. PLoS One (2011) 0.83
Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant (2014) 0.82
The effects of hydroalcoholic extract of Nigella sativa seed on oxidative stress in hippocampus of STZ-induced diabetic rats. Avicenna J Phytomed (2015) 0.82
Complex tissue-specific patterns and distribution of multiple RAGE splice variants in different mammals. Genome Biol Evol (2013) 0.82
Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults. Atherosclerosis (2014) 0.82
Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech Ageing Dev (2014) 0.82
D-Carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation. Br J Pharmacol (2012) 0.82
Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy. J Am Coll Cardiol (2016) 0.82
Molten globule of hemoglobin proceeds into aggregates and advanced glycated end products. PLoS One (2013) 0.81
Chronic kidney disease prediction is an inexact science: The concept of "progressors" and "nonprogressors". World J Nephrol (2014) 0.81
Predicting Type 1 Diabetes Candidate Genes using Human Protein-Protein Interaction Networks. J Comput Sci Syst Biol (2009) 0.80
The proteomics of drusen. Cold Spring Harb Perspect Med (2014) 0.80
Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. Biochim Biophys Acta (2016) 0.80
Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. J Diabetes Res (2016) 0.80
Type 2 diabetes and risk of low-energy fractures in postmenopausal women: meta-analysis of observational studies. Aging Clin Exp Res (2016) 0.79
Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management. Diabetes Metab Syndr Obes (2015) 0.79
Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci (2013) 0.79
Non enzymatic glycosylation of IgG and their urinary excretion in patients with diabetic nephropathy. Indian J Clin Biochem (2009) 0.79
Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study. Cardiovasc Diabetol (2016) 0.79
Reduced ovarian glyoxalase-I activity by dietary glycotoxins and androgen excess: a causative link to polycystic ovarian syndrome. Mol Med (2012) 0.79
Arterial Stiffness in Nonhypertensive Type 2 Diabetes Patients in Ghana. Int J Endocrinol (2016) 0.78
Factors associated with topographic changes of the optic nerve head induced by acute intraocular pressure reduction in glaucoma patients. Eye (Lond) (2010) 0.78
Reconvene and reconnect the antioxidant hypothesis in human health and disease. Indian J Clin Biochem (2010) 0.78
Pomegranate (Punicagranatum) juice decreases lipid peroxidation, but has no effect on plasma advanced glycated end-products in adults with type 2 diabetes: a randomized double-blind clinical trial. Food Nutr Res (2015) 0.78
DFT study of the mechanism of the reaction of aminoguanidine with methylglyoxal. J Mol Model (2014) 0.78
α-glucosidase and glycation inhibitory effects of costus speciosus leaves. BMC Complement Altern Med (2016) 0.77
ATP synthase subunit-β down-regulation aggravates diabetic nephropathy. Sci Rep (2015) 0.77
Heme oxygenase-1 inhibits neuropathic pain in rats with diabetic mellitus. Neural Regen Res (2012) 0.77
Correlation of advanced glycation endproducts estimated from skin fluorescence in first-degree relatives: the impact of adjustment for skin pigmentation. J Diabetes Sci Technol (2014) 0.77
Role of Moesin in Advanced Glycation End Products-Induced Angiogenesis of Human Umbilical Vein Endothelial Cells. Sci Rep (2016) 0.77
Relationship between glycemic control and histochemical myeloperoxidase activity in neutrophils in patients with type 2 diabetes. Diabetol Metab Syndr (2015) 0.77
The status of diabetic embryopathy. Ups J Med Sci (2016) 0.77
Prediabetes and Diabetes Are Associated With Arterial Stiffness in Older Adults: The ARIC Study. Am J Hypertens (2016) 0.77
Carboxymethyl lysine, an advanced glycation end product, and incident diabetes: a case-cohort analysis of the ARIC Study. Diabet Med (2015) 0.76
Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic mice. Diabetes Metab Syndr Obes (2015) 0.76
Vascular considerations in glaucoma patients of African and European descent. Acta Ophthalmol (2014) 0.76
Glycation of wood frog (Rana sylvatica) hemoglobin and blood proteins: in vivo and in vitro studies. Cryobiology (2009) 0.76
Chelation therapy after the trial to assess chelation therapy: results of a unique trial. Curr Opin Cardiol (2014) 0.76
Pudendal nerve injury reduces urethral outlet resistance in diabetic rats. Am J Physiol Renal Physiol (2010) 0.76
Retinal pigment epithelium differentiation of stem cells: current status and challenges. Crit Rev Biomed Eng (2009) 0.76
Genetic analysis of advanced glycation end products in the DHS MIND study. Gene (2016) 0.76
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med (2008) 4.25
Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes (2008) 4.13
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Mechanisms of diabetic complications. Physiol Rev (2013) 3.41
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res (2003) 2.69
Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J (2005) 2.66
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes (2007) 2.51
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes (2009) 2.34
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension (2003) 2.10
Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol (2011) 2.06
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes (2010) 1.95
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol (2005) 1.95
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol (2006) 1.88
E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes (2010) 1.85
NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation (2013) 1.78
Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res (2012) 1.78
Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation (2007) 1.74
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens (2003) 1.70
The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust (2006) 1.68
Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes (2004) 1.67
Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int (2011) 1.63
Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 1.59
Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol (2004) 1.58
Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int (2010) 1.57
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004) 1.51
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology (2002) 1.50
AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol (2007) 1.49
UKPDS and the legacy effect. N Engl J Med (2008) 1.49
TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) (2012) 1.49
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens (2002) 1.45
Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. Hypertension (2012) 1.43
Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation (2009) 1.40
ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab (2004) 1.40
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens (2005) 1.40
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis (2012) 1.38
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation (2004) 1.38
ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes (2008) 1.36
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes (2002) 1.36
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol (2005) 1.35
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J (2003) 1.33
Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol (2003) 1.32
The role of AGEs in cardiovascular disease. Curr Pharm Des (2008) 1.29
Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol (2004) 1.28
Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation (2002) 1.27
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care (2013) 1.26
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J (2005) 1.25
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol (2004) 1.23
Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy. Diabetes (2011) 1.22
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int (2004) 1.19
A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care (2002) 1.17
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol (2010) 1.16
Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol (2004) 1.15
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. Diabetes Care (2004) 1.15
Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol (2005) 1.14
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology (2006) 1.13
Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) (2013) 1.13
Mechanisms of diabetic nephropathy: role of hypertension. Hypertension (2006) 1.13
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol (2008) 1.12
Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens (2010) 1.12
Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. Endocrinology (2003) 1.11
Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol (2003) 1.11
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant (2006) 1.11
Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res (2010) 1.10
Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology (2002) 1.07
Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol (2004) 1.07
Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol (2002) 1.06
Advanced glycation end products and diabetic nephropathy. Am J Ther (2005) 1.05
Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways. J Biol Chem (2007) 1.05
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes (2004) 1.04
Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int (2004) 1.02
ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes (2002) 0.99
Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy. Nat Rev Nephrol (2011) 0.99
Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med (2011) 0.99
The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol (2003) 0.99
Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia (2014) 0.99
Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol (2013) 0.98
Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol (2003) 0.98
Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II. Kidney Int (2003) 0.96
Renoprotective effects of renin-angiotensin-system inhibitors. Lancet (2006) 0.96
Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol (2009) 0.96
Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology (Carlton) (2005) 0.96
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis (2009) 0.95
Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension (2004) 0.95
Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J Hypertens (2002) 0.94
Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med (2005) 0.94
Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes (2010) 0.94